Bringing Lean Startup Techniques to Life Sciences: MBA News | TopMBA.com

Bringing Lean Startup Techniques to Life Sciences: MBA News

By Tim Dhoul

Updated Updated

Quickening the pace at which findings and innovations in life sciences can be brought onto the commercial market is the aim behind a new collaborative program headed by faculty of UC Berkeley’s Haas School of Business.

This process is known as translational medicine – the ‘translation’ of research findings into procedures and products.

Haas School of Business believes that life sciences and translational medicine have much to gain by learning from the entrepreneurial principles of the ‘Lean Startup’ – something that has changed approaches to new businesses the world over.

Lean Startup techniques ditch conventional business plans in favor of working more closely on areas such as agile development, which focuses on cross-functional teamwork and early delivery.

“Hold on to your hats because we’re all in for one heck of a ride in a wave of new science startups,” said Haas School of Business’ Andre Marquis, a member of the teaching team for the life sciences program which is hosted by the innovation branch (I-Corps) of biomedical research facility, the National Institutes of Health (NIH).

Haas School of Business excited about future of translational medicine

“The future of translational medicine at the NIH is Lean – it’s fast, it works and it’s unlike anything else ever done,” said Steve Blank who teaches Lean Startup techniques at Haas School of Business and helped develop the program’s curriculum.

The program’s first cohort of 21 teams comes from a mixture of backgrounds relevant to translational medicine – in both life sciences and healthcare, for example.

Meanwhile, items on the Lean Startup lesson agenda include assessing any intellectual property and regulatory risk before advancing an idea to a design and build stage, as well as getting better acquainted with customer needs.

Indeed, Blank believes I-Corps is leading the way in its approach to translational medicine by encouraging lab scientists to engage more with customers when testing their hypotheses.  

“In the end we’re going to create new companies that bring life-saving drugs, devices and diagnostics to clinicians and patients faster and cheaper,” Blank asserts.

This article was originally published in . It was last updated in

Want more content like this Register for free site membership to get regular updates and your own personal content feed.